<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With MelanomaMaria Colombino, Giuseppe Palmieri, Corrado Rubino et al.|Journal of Clinical Oncology|2012Cited by 460
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Keith T. Flaherty, Shaheen Ahmed et al.|EClinicalMedicine|2023Cited by 26